Treatment of Group A Streptococcal Bacteremia

Initial Empiric Therapy

For suspected Group A streptococcal bacteremia, the Infectious Diseases Society of America recommends starting broad-spectrum coverage with vancomycin or linezolid PLUS piperacillin-tazobactam or a carbapenem, as the etiology can be polymicrobial or monomicrobial, including community-acquired MRSA, to reduce morbidity and mortality 1
The American College of Physicians suggests that initial presentations may not clearly distinguish between different bacterial etiologies, and delayed appropriate therapy increases morbidity and mortality, highlighting the importance of broad-spectrum coverage 1

The Infectious Diseases Society of America recommends penicillin G as the treatment of choice for Group A streptococcal bacteremia due to its proven efficacy, safety, narrow spectrum, and lack of resistance, with a dosing regimen of 12-24 million units/day IV for adults 2, 3
For severe invasive infections, including necrotizing fasciitis or toxic shock syndrome, the Infectious Diseases Society of America recommends penicillin G PLUS clindamycin, as clindamycin provides critical benefits by suppressing toxin production and maintaining efficacy during high bacterial inocula, with a dosing regimen of 600-900 mg IV every 8 hours 1

For non-immediate hypersensitivity reactions, the Infectious Diseases Society of America suggests first-generation cephalosporins, such as cefazolin, as acceptable alternatives, with a cross-reactivity risk with penicillin of less than 3% 2, 3
For immediate-type hypersensitivity reactions, the Infectious Diseases Society of America recommends clindamycin as the preferred alternative, with vancomycin as another option, although it has inferior activity against Group A streptococcus compared to beta-lactams 1, 2, 3

The Infectious Diseases Society of America emphasizes that penicillin monotherapy should never be used for necrotizing fasciitis or toxic shock syndrome, as the addition of clindamycin is life-saving, and that surgical consultation should not be delayed when necrotizing infection is suspected, as antibiotics alone are insufficient 1
The American College of Physicians warns against premature discontinuation of antibiotic therapy before completing the full course, as this increases the risk of relapse and suppurative complications 2

The Infectious Diseases Society of America recommends obtaining blood cultures to document clearance if bacteremia persists beyond 48-72 hours of appropriate therapy, and repeat imaging to identify undrained foci or metastatic infections, such as endocarditis or epidural abscess, if bacteremia persists 1